New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:50 EDTIDIXIdenix reports clinical data for HCV drug candidates - IDX719 and IDX184
Idenix Pharmaceuticals announced the presentation of safety and antiviral activity results for the company's clinical-stage hepatitis C virus, HCV, drug candidates IDX719, a next-generation pan-genotypic NS5A inhibitor, and IDX184, a nucleotide polymerase inhibitor. Idenix presented updated clinical findings from a three-day proof-of-concept study, which demonstrated that IDX719 was well-tolerated at daily doses up to 100 mg and showed potent antiviral activity across HCV genotypes 1-4, with mean maximal viral load reductions up to approximately 4.0 log10 IU/mL. The company also presented updated cardiovascular safety and antiviral activity data from the phase IIb study of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV). The IDX719 and IDX184 clinical data are being reported in poster presentations during the 63rd Annual Meeting for the American Association for the Study of Liver Diseases, AASLD, in Boston.
News For IDIX From The Last 14 Days
Check below for free stories on IDIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for IDIX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use